Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15223141 | 0.84 | — | — | |
| SCHEMBL15315159 | 0.83 | CES2 (0.67) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL23064078 | 0.83 | CES2 (0.67) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL23064089 | 0.83 | CES2 (0.67) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL15315161 | 0.83 | CES2 (0.67) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL15315165 | 0.83 | CES2 (0.67) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL6702677 | 0.82 | CES2 (0.54) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL7243144 | 0.80 | MEN1 (0.50) | CES2CYP4F2CYP4A11MEN1THRB | |
| SCHEMBL20317552 | 0.78 | CES2 (0.50) | CES2MEN1THRBHTTKMT2A | |
| SCHEMBL8379389 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612348-B2 | Process for purifying a mixture of diols | NOVAMONT S.P.A. (IT) | 2026-04-28 | — | — | US | claimed |
| US-20230212099-A1 | PROCESS FOR PURIFYING A MIXTURE OF DIOLS | NOVAMONT S.P.A. (IT) | 2023-07-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612348-B2 | Process for purifying a mixture of diols | ADH1C, BBOX1, ADH1A | CES2 2521/4885CYP4F2 634/4885CYP4A11 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.